Literature DB >> 28832487

Committee Opinion No. 716: The Role of the Obstetrician-Gynecologist in the Early Detection of Epithelial Ovarian Cancer in Women at Average Risk.

.   

Abstract

Ovarian cancer is the second most common type of female reproductive cancer, and more women die from ovarian cancer than from cervical cancer and uterine cancer combined. Currently, there is no strategy for early detection of ovarian cancer that reduces ovarian cancer mortality. Taking a detailed personal and family history for breast, gynecologic, and colon cancer facilitates categorizing women based on their risk (average risk or high risk) of developing epithelial ovarian cancer. Women with a strong family history of ovarian, breast, or colon cancer may have hereditary breast and ovarian cancer syndrome (BRCA mutation) or hereditary nonpolyposis colorectal cancer (Lynch syndrome), and these women are at increased risk of developing ovarian cancer. Women with these conditions should be referred for formal genetic counseling to better assess their cancer risk, including their risk of ovarian cancer. If appropriate, these women may be offered additional testing for early detection of ovarian cancer. The use of transvaginal ultrasonography and tumor markers (such as cancer antigen 125), alone or in combination, for the early detection of ovarian cancer in average-risk women have not been proved to reduce mortality, and harms exist from invasive diagnostic testing (eg, surgery) resulting from false-positive test results. The patient and her obstetrician-gynecologist should maintain an appropriate level of suspicion when potentially relevant signs and symptoms of ovarian cancer are present.

Entities:  

Mesh:

Year:  2017        PMID: 28832487     DOI: 10.1097/AOG.0000000000002299

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  10 in total

1.  Symptoms of Women With High-Risk Early-Stage Ovarian Cancer.

Authors:  John K Chan; Chunqiao Tian; Joshua P Kesterson; Bradley J Monk; Daniel S Kapp; Brittany Davidson; Sharon Robertson; Larry J Copeland; Joan L Walker; Robert M Wenham; Yovanni Casablanca; Nick M Spirtos; Krishnansu S Tewari; Jeffrey G Bell
Journal:  Obstet Gynecol       Date:  2022-02-01       Impact factor: 7.623

2.  Normalization of abnormal plasma amino acid profile-based indexes in patients with gynecological malignant tumors after curative treatment.

Authors:  Yukio Suzuki; Aya Tokinaga-Uchiyama; Taichi Mizushima; Yasuyo Maruyama; Tae Mogami; Nahoko Shikata; Atsuko Ikeda; Hiroshi Yamamoto; Etsuko Miyagi
Journal:  BMC Cancer       Date:  2018-10-12       Impact factor: 4.430

3.  Clinical Usefulness of Cancer Antigen (CA) 125, Human Epididymis 4, and CA72-4 Levels and Risk of Ovarian Malignancy Algorithm Values for Diagnosing Ovarian Tumors in Korean Patients With and Without Endometriosis.

Authors:  Kyung Hwa Shin; Hyung Hoi Kim; Byung Su Kwon; Dong Soo Suh; Jong Kil Joo; Ki Hyung Kim
Journal:  Ann Lab Med       Date:  2020-01       Impact factor: 3.464

4.  High-Volume Hospitals' Ovarian Cancer Care-Less Individual Approach or Better Treatment Results?

Authors:  Sonja Millert-Kalińska; Dominik Pruski; Marcin Przybylski; Małgorzata Stawicka-Niełacna; Edyta Mądry; Radosław Mądry
Journal:  Curr Oncol       Date:  2022-07-26       Impact factor: 3.109

5.  Malignancy Assessment Using Gene Identification in Captured Cells Algorithm for the Prediction of Malignancy in Women With a Pelvic Mass.

Authors:  Richard George Moore; Negar Khazan; Madeline Ann Coulter; Rakesh Singh; Michael Craig Miller; Umayal Sivagnanalingam; Brent DuBeshter; Cynthia Angel; Cici Liu; Kelly Seto; David Englert; Philip Meachem; Kyu Kwang Kim
Journal:  Obstet Gynecol       Date:  2022-09-08       Impact factor: 7.623

6.  Effects of Laparoscopic Hyperthermic Perfusion Therapy Combined with Adjuvant Treatment of Compound Yew Capsule on Ovarian Blood Flow Parameters and Immune Function in Patients with Ovarian Cancer.

Authors:  Mengya Su; Donghui Wang; Ping Huang
Journal:  Evid Based Complement Alternat Med       Date:  2022-07-13       Impact factor: 2.650

7.  Description of Genetic Variants in BRCA Genes in Mexican Patients with Ovarian Cancer: A First Step towards Implementing Personalized Medicine.

Authors:  Jesus Rolando Delgado-Balderas; Maria Lourdes Garza-Rodriguez; Gabriela Sofia Gomez-Macias; Alvaro Barboza-Quintana; Oralia Barboza-Quintana; Ricardo M Cerda-Flores; Ivett Miranda-Maldonado; Hugo Mauricio Vazquez-Garcia; Lezmes Dionicio Valdez-Chapa; Mauro Antonio-Macedo; Michael Dean; Hugo A Barrera-Saldaña
Journal:  Genes (Basel)       Date:  2018-07-11       Impact factor: 4.096

8.  PMS2 germline mutation c.943C>T (p.Arg315*)-induced Lynch syndrome-associated ovarian cancer.

Authors:  Xiaoqing Guo; Weimin Wu; Hao Gao; Xiaofeng Li; Qizhi He; Yong Zhu; Na Liu
Journal:  Mol Genet Genomic Med       Date:  2019-05-05       Impact factor: 2.183

9.  Detection of early stage ovarian cancer in a large community cohort.

Authors:  Elizabeth J Suh-Burgmann; Mubarika Alavi
Journal:  Cancer Med       Date:  2019-09-30       Impact factor: 4.452

10.  Variation in the initial assessment and investigation for ovarian cancer in symptomatic women: a systematic review of international guidelines.

Authors:  Garth Funston; Marije Van Melle; Marie-Louise Ladegaard Baun; Henry Jensen; Charles Helsper; Jon Emery; Emma J Crosbie; Matthew Thompson; Willie Hamilton; Fiona M Walter
Journal:  BMC Cancer       Date:  2019-11-01       Impact factor: 4.430

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.